Management Team




  • Gerard Brett
  • Gerard Brett - Co-founder and Chief Executive Officer

    Ger has over 25 years international business and company management experience with 18 years in Medtech. Previously, he worked in the USA with Ciba Geigy Corporation in engineering polymer R&D, operations and technical marketing and with Boston Scientific in the USA and Ireland in production and program management for the Vascular division. While with Boston, he was responsible for managing the transfer of over 25 stent and balloon product lines into the Galway manufacturing facility from around the world, and played a key role in the integration and manufacturing of the Schneider products into Galway.

    He co-founded and was the CEO of Zerusa Limited, where he led the development and commercialisation of its hemostasis product in the EU and USA and positioned the company for acquisition by Vascular Solutions.

  • Chris Martin
  • Christopher Martin, PhD - Co-founder and Chief Technical Officer

    Chris has over twenty five years of experience in the medical device industry – with 20 years in vessel closure, working with both start-up and multinational companies including American Cyanamid, David + Geck, Acuflex Microsurgical, Storz instruments, Johnson & Johnson, Nova Science and Zerusa. He has senior level experience in all aspects of research and product development, from concept to market, including: IP protection, development, pre-clinical, clinical, regulatory, technology transfer, manufacturing and production. He has tertiary qualifications in Engineering, Medicine and Biomedical Engineering. He is an inventor on at least 13 granted patents and over 30 applications worldwide.

  • Paul Teirstein, MD
  • Paul Teirstein, MD - Chief Medical Officer

    Paul Teirstein, MD, is the chief of cardiology and director of interventional cardiology for Scripps Clinic and director of the Scripps Prebys Cardiovascular Institute for Scripps Health. He received training at the Mount Sinai School of Medicine, the Brigham and Women’s Hospital, Stanford University, the Mid-America Heart Institute, and the National Institutes of Health.

    Dr. Teirstein has a primary focus on complex coronary interventions and new technology development. His recent areas of investigation include new technology for minimally invasive transcatheter aortic valve replacement (PARTNER trial) and transcatheter treatment of hypertension (Simplicity trial). He is a member of multiple professional societies including the American Heart Association, the Society of Cardiac Angiography and Interventions, and is a fellow of the American College of Cardiology.